.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
QuintilesIMS
Accenture
AstraZeneca
Harvard Business School
Dow
Deloitte
Baxter
Queensland Health
US Army

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and/or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis/cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery.
Inventor(s): Brinker; C. Jeffrey (Albuquerque, NM), Carnes; Eric C. (Albuquerque, NM), Ashley; Carlee Erin (Albuquerque, NM), Willman; Cheryl L. (Albuquerque, NM)
Assignee: STC.UNM (Albuquerque, NM) Sandia Corporation (Albuquerque, NM)
Application Number:14/113,371
Patent Claims:1. A cell-targeting porous protocell composition comprising a plurality of protocells, the protocells comprising: a nanoporous silica or metal oxide core with a supported lipid bilayer; a Met binding peptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, wherein the Met binding peptide is attached to the supported lipid bilayer; a fusogenic peptide that promotes endosomal escape, wherein the fusogenic peptide is attached to the supported lipid bilayer; and a cargo loaded into the protocell, wherein the cargo is selected from the group consisting of: double stranded linear DNA; plasmid DNA; a drug; an imaging agent; small interfering RNA; small hairpin RNA; and microRNA; wherein the cargo is optionally conjugated to a nuclear localization sequence.

2. The protocell composition according to claim 1 wherein said silica cores of the protocells are spherical and range in diameter from about 10 nm to about 250 nm.

3. The protocell composition according to claim 2 wherein said silica cores of the protocells have a mean diameter of about 150 nm.

4. The protocell composition according to any one of claims 1-3 wherein said protocells are monodisperse.

5. The protocell composition according to any one of claims 1-3 wherein said protocells are polydisperse.

6. The protocell composition according to claim 1 wherein said lipid bilayer is comprised of lipids selected from the group consisting of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyi-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-[phosphor-L-serine] (DOPS), 1,2-dioleoyl-3-trimethylammonium-propane (18:1 DOTAP), 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DOPG), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (18:1 PEG-2000 PE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (16:0 PEG-2000 PE), 1-Oleoyl-2-[12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]lauroyl]-sn-Glyce- ro-3-Phosphocholine (18:1-12:0 NBD PC), 1-palmitoyl-2-{12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]lauroyl}-sn-gl- ycero-3-phosphocholine (16:0-12:0 NBD PC), cholesterol and mixtures thereof.

7. The protocell composition according to claim 6 wherein said lipid bilayer comprises DOPC in combination with DOPE.

8. The protocell composition according to claim 6 wherein said lipid bilayer comprises DOTAP, DOPG, DOPC or mixtures thereof.

9. The protocell composition according to claim 6 wherein said lipid bilayer comprises DOPG and DOPC.

10. The protocell composition according to claim 6 wherein said lipid bilayer comprises cholesterol.

11. The protocell composition according to claim 1 wherein said lipid bilayer comprises DOPC in combination with about 5 wt % DOPE, about 30 wt % cholesterol, and about 10 wt % PEG-2000 PE (18:1).

12. The protocell composition according to claim 1 wherein lipid bilayer comprises about 5% by weight DOPE, about 30% by weight cholesterol, and about 60% by weight DOPC and/or DPPC.

13. The protocell composition according to claim 1 wherein the lipid bilayer comprises PEG-conjugated to DOPE.

14. The protocell composition according to claim 1 wherein said protocells further comprise an additional targeting peptide.

15. The protocell composition according to claim 14 wherein said targeting peptide is a SP94 peptide.

16. The protocell composition according to claim 14 wherein said targeting peptide is SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8.

17. The protocell composition according to claim 1 wherein said fusogenic peptide is H5WYG peptide (SEQ ID NO: 13) or an eight mer of polyarginine (SEQ ID NO: 14).

18. The protocell composition according to claim 17 wherein said fusogenic peptide is SEQ ID NO: 13.

19. The protocell composition according to claim 1 wherein the cargo comprises plasmid DNA.

20. The protocell composition according to claim 19 wherein said plasmid DNA is supercoiled or packaged plasmid DNA.

21. The protocell composition according to claim 20 wherein said DNA is both supercoiled and packaged plasmid DNA.

22. The protocell according to claim 19 wherein said plasmid DNA is conjugated to a nuclear localization sequence.

23. The protocell composition according to claim 19 wherein said plasmid DNA is histone-packaged supercoiled plasmid DNA and comprises a mixture of human histone proteins.

24. The protocell composition according to any of claim 1 wherein said plasmid DNA encodes a polypeptide toxin, a small hairpin RNA (shRNA) or a small interfering RNA (siRNA).

25. The protocell composition according to claim 24 wherein said polypeptide toxin is selected from the group consisting of ricin toxin chain-A and diphtheria toxin chain-A.

26. The protocell composition according to claim 24 wherein said shRNA or said siRNA induces apoptosis of a cell.

27. The protocell composition according to claim 1 wherein said DNA encodes a reporter protein.

28. The protocell composition according to claim 27 wherein said reporter protein is green fluorescent protein or red fluorescent protein.

29. The protocell composition according to claim 27 wherein said MET binding peptide is a peptide according to SEQ ID NO: 1.

30. The protocell composition according to claim 1 wherein said nuclear localization sequence is a peptide according to SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12.

31. The protocell composition according to claim 1 wherein said cargo comprises said drug, and said drug is an anticancer agent.

32. The protocell composition according to claim 31 wherein said anticancer agent is everolimus, trabectedin, abraxane, TLK 286, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, a FLT-3 inhibitor, a VEGFR inhibitor, an EGFR TK inhibitor, an aurora kinase inhibitor, a PIK-1 modulator, a Bcl-2 inhibitor, an HDAC inhibitor, a c-MET inhibitor, a PARP inhibitor, a Cdk inhibitor, an EGFR TK inhibitor, an IGFR-TK inhibitor, an anti-HGF antibody, a PI3 kinase inhibitors, an AKT inhibitor, a JAK/STAT inhibitor, a checkpoint-1 or 2 inhibitor, a focal adhesion kinase inhibitor, a Map kinase kinase (mek) inhibitor, a VEGF trap antibody, pemetrexed, erlotinib, dasatanib, nilotinib, decatanib, panitumumab, amrubicin, oregovomab, Lep-etu, nolatrexed, azd2171, batabulin, ofatumumab, zanolimumab, edotecarin, tetrandrine, rubitecan, tesmilifene, oblimersen, ticilimumab, ipilimumab, gossypol, Bio 111 , 131-I-TM-601, ALT-110, BIO 140, CC 8490, cilengitide, gimatecan, IL13-PE38QQR, INO 1001, IPdR.sub.1 KRX-0402, lucanthone, LY 317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan, Xr 311, romidepsin, ADS-100380, sunitinib, 5-fluorouracil, vorinostat, etoposide, gemcitabine, doxorubicin, 5'-deoxy-5-fluorouridine, vincristine, temozolomide, ZK-304709, seliciclib; PD0325901, AZD-6244, capecitabine, L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]- benzoyl]-, disodium salt, heptahydrate, camptothecin, PEG-labeled irinotecan, tamoxifen, toremifene citrate, anastrazole, exemestane, letrozole, DES(diethylstilbestrol), estradiol, estrogen, conjugated estrogen, bevacizumab, IMC-1C11, CHIR-258,); 3-[5-(methylsulfbnylpiperadinemethyl)-indolyij-quinolone, vatalanib, AG-013736, AVE-0005, the acetate salt of [D-Ser(Bu t) 6, Azgly 10](pyro-Glu-His-Trp-Ser-Tyr-D-Ser(Bu t)-Leu-Arg-Pro-Azgly-NH.sub.2 acetate [C.sub.59H.sub.84N.sub.18Oi.sub.4 --(C.sub.2H.sub.4 O.sub.2).sub.x where x=1 to 2.4], goserelin acetate, leuprolide acetate, triptorelin pamoate, medroxyprogesterone acetate, hydroxyprogesterone caproate, megestrol acetate, raloxifene, bicalutamide, flutamide, nilutamide, megestrol acetate, CP-724714; TAK-165, HKI-272, erlotinib, lapatanib, canertinib, ABX-EGF antibody, erbitux, EKB-569, PKI-166, GW-572016, Ionafamib, BMS-214662, tipifarnib; amifostine, NVP-LAQ824, suberoyl analide hydroxamic acid, valproic acid, trichostatin A, FX-228, SU11248, sorafenib, KRN951, aminoglutethimide, arnsacrine, anagrelide, L-asparaginase, Bacillus Calmette-Guerin (BCG) vaccine, bleomycin, buserelin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, diethylstilbestrol, epirubicin, fludarabine, fludrocortisone, fluoxyrnesterone, flutamide, gemcitabine, gleevac, hydroxyurea, idarubicin, ifosfamide, imatmib, leuprolide, levamisole, lomustine, mechlorethamine, melphalan, 6-mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, octreotide, oxalipiatin, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, teniposide, testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vindesine, 13-cis-retinoic acid, phenylalanine mustard, uracil mustard, estramustine, altretamine, floxuridine, 5-deooxyuridine, cytosine arabinoside, 6-mecaptopurine, deoxycofbrmycin, calcitriol, valrubicin, mithrarnycin, vinblastine, vinoretbine, topotecan, razoxin, marimastat, COL-3, neovastat, BMS-275291, squalamine, endostatin, SU5416, SU6668, EMD121974, interleukin-12, IM862, angiostatin, vitaxin, droloxifene, idoxyfene, spironolactone, finasteride, cimitidine, trastuzumab, denileukin diftitox, gefitinib, bortezimib, paclitaxel, cremophor-free paclitaxel, docetaxel, epithilone B, BMS-247550, BMS-310705, droloxifene, 4-hydroxytamoxifen, pipendoxifene, ERA-923, arzoxifene, fulvestrant, acolbifene, lasolbxifene, idoxifene, TSE-424, HMR-3339, ZK186619, topotecan, PTK787/ZK 222584, VX-745, PD 184352, rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, temsirolimus, AP-23573, RAD001, ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684, LY293646, wortmannin, ZM336372, L-779,450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zolendronate, prednisone, cetuximab, granulocyte macrophage colony-stimulating factor, histrelin, pegylated interferon alfa-2a, interferon alfa-2a, pegylated interferon alfa-2b, interferon alfa-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-11, dexrazoxane, alemtuzumab, all-transretinoic acid, ketoconazole, interleukin-2, megestrol, immune globulin, nitrogen mustard, methylprednisolone, ibritgumomab tiuxetan, androgens, decitabine, hexamethylmelamine, bexarotene, tositunioniab, arsenic trioxide, cortisone, editronate, mitotane, cyclosporine, liposomal daunorubicin, Edwina-asparaginase, strontium 89, casopitant, netupitant, an NK-1 receptor antagonists, palonosetron, aprepitant, diphenhydramine, hydroxyzine, metoclopramide, lorazepam, alprazolam, haloperidol, droperidol, dronabinol, dexamethasone, methyiprednisolone, prochlorperazine, granisetron, ondansetron, dolasetron, tropisetron, pegfilgrastim, erythropoietin, epoetin alfa, darbepoetin alfa or a mixture thereof.

33. A pharmaceutical composition comprising the protocell composition according to claim 1 in an amount effective for effecting a therapeutic effect in combination with a pharmaceutically acceptable carrier, additive or excipient.

34. The pharmaceutical composition according to claim 33 further comprising a drug which is not disposed as cargo within the protocell.

35. The pharmaceutical composition according to claim 34 wherein said drug is an anti-cancer agent or an anti-viral agent.

36. The pharmaceutical composition according to claim 33 in parenteral dosage form.

37. The pharmaceutical composition according to claim 36 wherein said dosage form is intradermal, intramuscular, intraosseous, intraperitoneal, intravenous, subcutaneous or intrathecal.

38. The pharmaceutical composition according to claim 33 in topical or transdermal dosage form.

39. A protocell comprising a nanoporous silica core with a supported lipid bilayer and a MET binding peptide according to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4 or SEQ ID NO: 5, attached to the supported lipid bilayer.

40. The photocell according to claim 39 wherein said protocell further comprises at least one component selected from a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA; a plasmid DNA; double stranded linear DNA; a drug; an imaging agent; small interfering RNA; small hairpin RNA; or micro RNA, wherein said plasmid or double stranded linear DNA, said drug, said imaging agent and/or said small interfering, small hairpin or micro RNA are further conjugated with a nuclear localization sequence.

41. The protocell according to claim 40 wherein said drug comprises at least one one anticancer agent.

42. The protocell according to claim 41 wherein said anticancer agent is selected from everollimus, trabectedin, abraxane, TLK 286,AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, a FLT-3 inhibitor, a VEGFR inhibitor, an EGFR TK inhibitor, an aurora kinase inhibitor, a PIK-1 modulator, a Bcl-2 inhibitor, an HDAC inhibitor, a c-MET inhibitor, a PARP inhibitor, a Cdk inhibitor, an EGFR TK inhibitor, an IGFR-TK inhibitor, an anti-HGF antibody, a PI3 kinase inhibitors, an AKT inhibitor, a JAK/STAT inhibitor, a checkpoint-1 or 2 inhibitor, a focal adhesion kinase inhibitor, a Map kinase kinase (mek) inhibitor, a VEGF trap antibody, pemetrexed, erlotinib, dasatanib, nilotinib, decatanib, panitumumab, amrubicin, oregovomab, Lep-etu, nolatrexed, azd2171, batabulin, ofatumumab, zanolimumab, edotecarin, tetrandrine, rubitecan, tesmilifene, ohlimersen, ticilimumab, ipilimumab, gossypol, Bio 111, 131-I-TM-601, ALT-110, BIO 140, CC 8490, cilengitide, gimatecan, IL13-PE38QQR, INO 1001, IPdR.sub.1 KRX-0402, lucanthone, LY 317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan, Xr 311, romidepsin, ADS-100380, sunitinib, 5-fluorouracil, vorinostat, etoposide, gemcitabine, doxorubicin, 5'-deoxy-5-fluorouridine, vincristine, temozolomide, ZK-304709, seliciclib; PD0325901, AZD-6244, capecitabine, L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]- benzoyl]-, disodium salt, heptahydrate, camptothecin, PEG-labeled irinotecan, tamoxifen, toremifene citrate, anastrazole, exemestane, letrozole, DES(diethylstilbestrol), estradiol, estrogen, conjugated estrogen, bevacizumab, IMC-1C11, CHIR-258,); 3-[5-(methylsulfonylpiperadinemethyl)-indolyij-quinolone, vatalanib, AG-013736, AVE-0005, the acetate salt of [D-Ser(Bu t) 6, Azgly 10] (pyro-Glu-His-Trp-Ser-Tyr-D-Ser(Bu t)-Leu-Arg-Pro-Azgly-NH.sub.2 acetate [C.sub.59H.sub.84N.sub.18Oi.sub.4-(C.sub.2H.sub.4O.sub.2)x where x=1 to 2.4], goserelin acetate, leuprolide acetate, triptorelin pamoate, medroxyprogesterone acetate, hydroxyprogesterone caproate, megestrol acetate, raloxifene, bicalutamide, flutamide, nilutamide, megestrol acetate, CP-724714; TAK-165, HKI-272, erlotinib, lapatanib, canertinib, ABX-EGF antibody, erbitux, EKB-569, PKI-166, GW-572016, Ionafarnib, BMS-214662, tipifarnib; amilbstine, NVP-LAQ824, suberoyl analide hydroxamic acid, valproic acid, trichostatin A, FK-228, SU11248, sorafenib, KRN951, aminogiutethimide, arnsacrine, anagrelide, L-asparaginase, Bacillus Calmette-Guerin (BCG) vaccine, bleomycin, buserelin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, diethylstilbestrol, epirubicin, fludarabine, fludrocortisone, fluoxymesterone, flutamide, gemcitabine, gleevac, hydroxyurea, idarubicin, ifosfamide, imatinib, leuprolide, levamisole, lomustine, mechlorethamine, melphalan, 6-mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, octreotide, oxaliplatin, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, teniposide, testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vindesine, 13-cis-retinoic acid, phenylalanine mustard, uracil mustard, estramustine, altretamine, floxuridine, 5-deooxyuridine, cytosine arabinoside, 6-mecaptopurine, deoxycoformycin, calcitriol, valrubicin, mithramycin, vinblastine, vinorelbine, topotecan, razoxin, marimastat, COL-3, neovastat, BMS-275291, squalamine, endostatin, SU5416, SU6668, EMD121974, interleukin-12, IM862, angiostatin, vitaxin, droloxifene, idoxyfene, spironolactone, finasteride, cimitidine, trastuzumab, denileukin diftitox, gefitinib, bortezimib, paclitaxel, cremophor-free paclitaxel, docetaxel, epithilone B, BMS-247550, BMS-310705, droloxifene, 4-hydroxytamoxifen, pipendoxifene, ERA-923, arzoxifene, fulvestrant, acoibifene, lasofoxitene, idoxifene, TSE-424, HMR-3339, ZK186619, topotecan, PTK787/ZK 222584, VX-745, PD 184352, rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, temsirolimus, AP-23573, RAD001, ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684, LY293646, wortmannin, ZM336372, L-779,450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zolendronate, prednisone, cetuximab, granulocyte macrophage colony-stimulating factor, histrelin, pegylated interferon alfa-2a, interferon alfa-2a, pegylated interferon alfa-2b, interferon alfa-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-11, dexrazoxane, alerntuzumab, all-transretinoic acid, ketoconazole, interleukin-2, megestrol, immune globulin, nitrogen mustard, methylprednisolone, ibritgunioniab tiuxetan, androgens, decitabine, hexamethylmelamine, bexarotene, tositumomab, arsenic trioxide, cortisone, editronate, mitotane, cyclosporine, liposomal daunorubicin, Edwina-asparaginase, strontium 89, casopitant, netupitant, an NK-1 receptor antagonists, palonosetron, aprepitant, diphenhydramine, hydroxyzine, metoclopramide, lorazepam, alprazolam, haloperidol, droperidol, dronabinol, dexamethasone, methylprednisolone, prochlorperazine, granisetron, ondansetron, dolasetron, tropisetron, pegfilgrastim erythropoietin, epoetin alfa, darbepoetin alfa or mixtures thereof.

43. The protocell according to claim 40 wherein said plasmid or double stranded linear DNA encodes at least one reporter molecule.

44. The protocell according to claim 40 comprising the plasmid DNA, wherein said plasmid DNA optionally encodes a nuclear localization sequence.

45. A method of treating cancer in a patient comprising administering to the cancer in the patient in need thereof an effective amount of a composition comprising a population of protocells according to claim 1 wherein the cargo is an anticancer agent.

Summary for Patent: ► Subscribe

PCT Information
PCT FiledApril 27, 2012PCT Application Number:PCT/US2012/035529
PCT Publication Date:November 01, 2012PCT Publication Number: WO2012/149376

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Schering
INTRON A
interferon alfa-2b
VIAL1031320011986-06-04► Subscribe STC.UNM (Albuquerque, NM) Sandia Corporation (Albuquerque, NM) Brinker; C. Jeffrey (Albuquerque, NM), Carnes; Eric C. (Albuquerque, NM), Ashley; Carlee Erin (Albuquerque, NM), Willman; Cheryl L. (Albuquerque, NM) ► SubscribeRXsearch
Schering
INTRON A
interferon alfa-2b
VIAL1031320021986-06-04► Subscribe STC.UNM (Albuquerque, NM) Sandia Corporation (Albuquerque, NM) Brinker; C. Jeffrey (Albuquerque, NM), Carnes; Eric C. (Albuquerque, NM), Ashley; Carlee Erin (Albuquerque, NM), Willman; Cheryl L. (Albuquerque, NM) ► SubscribeRXsearch
Schering
INTRON A
interferon alfa-2b
VIAL1031320031986-06-04► Subscribe STC.UNM (Albuquerque, NM) Sandia Corporation (Albuquerque, NM) Brinker; C. Jeffrey (Albuquerque, NM), Carnes; Eric C. (Albuquerque, NM), Ashley; Carlee Erin (Albuquerque, NM), Willman; Cheryl L. (Albuquerque, NM) ► SubscribeRXsearch
Amgen
EPOGEN/PROCRIT
epoetin alfa
VIAL; SINGLE-USE1032340011989-06-01► Subscribe STC.UNM (Albuquerque, NM) Sandia Corporation (Albuquerque, NM) Brinker; C. Jeffrey (Albuquerque, NM), Carnes; Eric C. (Albuquerque, NM), Ashley; Carlee Erin (Albuquerque, NM), Willman; Cheryl L. (Albuquerque, NM) ► SubscribeRXsearch
Amgen
EPOGEN/PROCRIT
epoetin alfa
VIAL; MULTIDOSE1032340021989-06-01► Subscribe STC.UNM (Albuquerque, NM) Sandia Corporation (Albuquerque, NM) Brinker; C. Jeffrey (Albuquerque, NM), Carnes; Eric C. (Albuquerque, NM), Ashley; Carlee Erin (Albuquerque, NM), Willman; Cheryl L. (Albuquerque, NM) ► SubscribeRXsearch
Amgen
EPOGEN/PROCRIT
epoetin alfa
VIAL; MULTIDOSE1032340031989-06-01► Subscribe STC.UNM (Albuquerque, NM) Sandia Corporation (Albuquerque, NM) Brinker; C. Jeffrey (Albuquerque, NM), Carnes; Eric C. (Albuquerque, NM), Ashley; Carlee Erin (Albuquerque, NM), Willman; Cheryl L. (Albuquerque, NM) ► SubscribeRXsearch
Amgen
EPOGEN/PROCRIT
epoetin alfa
VIAL; SINGLE-USE1032340041989-06-01► Subscribe STC.UNM (Albuquerque, NM) Sandia Corporation (Albuquerque, NM) Brinker; C. Jeffrey (Albuquerque, NM), Carnes; Eric C. (Albuquerque, NM), Ashley; Carlee Erin (Albuquerque, NM), Willman; Cheryl L. (Albuquerque, NM) ► SubscribeRXsearch
Amgen
EPOGEN/PROCRIT
epoetin alfa
VIAL; SINGLE-USE1032340051989-06-01► Subscribe STC.UNM (Albuquerque, NM) Sandia Corporation (Albuquerque, NM) Brinker; C. Jeffrey (Albuquerque, NM), Carnes; Eric C. (Albuquerque, NM), Ashley; Carlee Erin (Albuquerque, NM), Willman; Cheryl L. (Albuquerque, NM) ► SubscribeRXsearch
Amgen
EPOGEN/PROCRIT
epoetin alfa
VIAL; SINGLE-USE1032340061989-06-01► Subscribe STC.UNM (Albuquerque, NM) Sandia Corporation (Albuquerque, NM) Brinker; C. Jeffrey (Albuquerque, NM), Carnes; Eric C. (Albuquerque, NM), Ashley; Carlee Erin (Albuquerque, NM), Willman; Cheryl L. (Albuquerque, NM) ► SubscribeRXsearch
Amgen
EPOGEN/PROCRIT
epoetin alfa
VIAL; SINGLE-USE1032340071989-06-01► Subscribe STC.UNM (Albuquerque, NM) Sandia Corporation (Albuquerque, NM) Brinker; C. Jeffrey (Albuquerque, NM), Carnes; Eric C. (Albuquerque, NM), Ashley; Carlee Erin (Albuquerque, NM), Willman; Cheryl L. (Albuquerque, NM) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Dow
Daiichi Sankyo
Julphar
Farmers Insurance
Accenture
Cantor Fitzgerald
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot